Abstract: Objective To study the in-hospital mortality rate of recombinant human tissue-type plasrninogen activator(rt-PA) and urokinase(UK) from 2005 to 2009. Methods We retrospectively analyzed the type of thrombolytic agents and cause of death in ST elevated acute myocardial infarctiong patients(n=57) and pulmonary thromboembolism pa-tients(n=60). Results In the 117cases, ten patients died in hospital due to cardiac shock(n=6)、cardiac rupture(n=3) and ventricular fibrillation(n=1). No case died of bleeding complication. Seven of ten deaths suffered acute myocardial infarction. The other 3 deathes due to cardiac shock suffered pulmonary thromboembolism. About 84%(98 cases) patients used rt-PA, of whom seven patients died. In the patients using UK(n=19), 3 cases died. Conclusion The in-hospital mortality rate of the patients using thrombolytic therapy was mainly associated with underlying diseases. The scientific and standardized thrombolytic therapy is safe.

Key words: recombinant human tissue-type plasrninogen activator, urokinase, in-hospital mortality rate